Next-generation sequencing of cancer consensus genes in lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 8, 2013, Pages 1831-1835

  Hüllein, Jennifer ^a   Jethwa, Alexander ^a   Stolz, Tatjana ^a   Blume, Carolin ^a   Sellner, Leopold ^a,b   Sill, Martin ^a   Langer, Christian ^c   Jauch, Anna ^b   Paruzynski, Anna ^a   Von Kalle, Christof ^a   Schmidt, Manfred ^a   Glimm, Hanno ^a   Zenz, Thorsten ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Cancer consensus genes; Chronic lymphocytic leukemia; CLL; Lymphoma; Multiple myeloma; Targeted resequencing

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; NOTCH1 RECEPTOR; ONCOPROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR EZH2;

CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; CONSENSUS SEQUENCE; GENE MUTATION; GENE TARGETING; GENOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA; MOLECULAR CLONING; MULTIPLEX POLYMERASE CHAIN REACTION; ONCOGENE N RAS; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR GENE;

AMINO ACID SUBSTITUTION; CELL TRANSFORMATION, NEOPLASTIC; EXONS; GENE FREQUENCY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHOMA; MUTATION; ONCOGENES;

EID: 84880311623     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.796053     Document Type: Conference Paper

References (14)

1. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma wiTheZH2-Activating mutations. Nature 2012 ; 492 : 108-112
2. Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. NEngl J Med 2012; 366: 2038-2040
3. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifi es recurrent mutations in chronic lymphocytic leukaemia. Nature 2011 ; 475 : 101-105
4. Quesada V, Conde L, Villamor N, et a l. Exome sequencing identifi es recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011; 44: 47-52
5. Rossi D, Rasi S, Fabbri G, et a l. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2011 ; 119 : 521-529
6. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012 ; 26 : 1458-1461
7. Hallek M, Cheson B D, Catovsky D, et a l. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 ; 111 : 5446-5456
8. Thomas R K, Nickerson E, Simons J F, et a l. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006; 12: 852-855
9. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. NEngl J Med 2011 ; 365 : 2497-2506
10. Knight SJ, Yau C, Cliff ord R, et a l. Quantifi cation of subclonal distributions of recurrent genomic aberrations in paired pre-Treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia 2012; 26: 1564-1575
11. Skowronska A, Parker A, Ahmed G, et a l. Biallelic ATM inactivation signifi cantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial. J Clin Oncol 2012 ; 30 : 4524-4532
12. Chapman M A, Lawrence M S, Keats J J, et a l. Initial genome sequencing and analysis of multiple myeloma. Nature 2011 ; 471 : 467-472
13. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom s macroglobulinemia. NEngl J Med 2012 ; 367 : 826-833
14. Zenz T, Krober A, Scherer K, et a l. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-Term followup. Blood 2008 ; 112 : 3322-3329